Clinical Trial Update: Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immunogenicity of a recombinant Respiratory Syncytial Virus vaccine in adults 18 years and older; study is active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Recombinant Respiratory Syncytial Virus Vaccine (RSV vaccine (recombinant))

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Respiratory Syncytial Virus Infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING